| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vivo |
In female rats, the combination of Alphaxalonet and Alphadoloneacetate (anesthetized with a 3:1 mixture of Alphaxalone and Alphadoloneacetate) inhibits pulsatile secretion and suppresses the estrogen-stimulated luteinizing hormone (LH) surge [2]. In ovariectomized rats, a single intraperitoneal injection of aldolone acetate at a dose of 14 mL/kg lowers serum LH concentrations [3].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: Female rats of inbred Wistar origin (intramuscularinjection of 20 µg/100g estradiol benzoate) [2]
Doses: Anesthetized with a 3:1 mixture of Alphaxalone and Alphadolone acetate Route of Administration: intramuscularinjection Experimental Results: Blocks the estrogen-stimulated LH surge and impairs pulsatile secretion. Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat (orchidectomized; age 90-120 days, weight 300-350 g) [3] Doses: 14 mL/kg Route of Administration: intraperitoneal (ip) injection; single dose Experimental Results: diminished serum LH concentration . |
| References |
[1]. Nadeson R, et al. Antinociceptive properties of neurosteroids II. Experiments with Saffan and its components alphaxalone and alphadolone to reveal separation of anaesthetic and antinociceptive effects and the involvement of spinal cord GABA(A) receptors. Pain. 2000 Oct;88(1):31-39.
[2]. Dyer RG, Mansfield S. Anaesthesia with alphaxalone plus alphadolone acetate blocks the oestrogen-stimulated LH surge and impairs pulsatile LH secretion in ovariectomized female rats. J Endocrinol. 1984 Jul;102(1):27-31. [3]. Emanuele MA, et al. Anaesthesia with alphaxalone plus alphadolone acetate decreases serum concentrations of LH in castrated rats. J Endocrinol. 1987 Nov;115(2):221-3. |
| Additional Infomation |
Acetic acid [2-[(3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-11-oxo-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] ester is a corticosteroid hormone.
See also: Alfadolone (annotation moved to). |
| Molecular Formula |
C23H34O5
|
|---|---|
| Molecular Weight |
390.51306
|
| Exact Mass |
390.241
|
| CAS # |
23930-37-2
|
| PubChem CID |
24733
|
| Appearance |
White to off-white solid powder
|
| Density |
1.164g/cm3
|
| Boiling Point |
523.6ºC at 760mmHg
|
| Flash Point |
175.1ºC
|
| Vapour Pressure |
3.75E-13mmHg at 25°C
|
| Index of Refraction |
1.53
|
| LogP |
3.317
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
687
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CC(OCC(C1CCC2C3CCC4CC(CCC4(C)C3C(CC12C)=O)O)=O)=O
|
| InChi Key |
QRJOQYLXZPQQMX-FWROMSNXSA-N
|
| InChi Code |
InChI=1S/C23H34O5/c1-13(24)28-12-20(27)18-7-6-17-16-5-4-14-10-15(25)8-9-22(14,2)21(16)19(26)11-23(17,18)3/h14-18,21,25H,4-12H2,1-3H3/t14-,15+,16-,17-,18+,21+,22-,23-/m0/s1
|
| Chemical Name |
[2-[(3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-11-oxo-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~640.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5608 mL | 12.8038 mL | 25.6075 mL | |
| 5 mM | 0.5122 mL | 2.5608 mL | 5.1215 mL | |
| 10 mM | 0.2561 mL | 1.2804 mL | 2.5608 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
